Antiinfectives for Systemic Use, 2. Antimycotics (Antifungals) and Antimycobacterials
First published: 29 September 2016
Abstract
The article contains sections titled:
| 1. | Introduction |
| 2. | J02 Antimycotics |
| 3. | J04 Antimycobacterials |
| 3.1 | J04A Drugs for Treatment of Tuberculosis |
| 3.2 | J04B Drugs for Treatment of Lepra (Leprosy) |
References
- 1
Suerbaum, S.
et al. (eds.) (2012) Medizinische Mikrobiologie und Infektiologie, 7th edn
Springer, [G. Haase: Mykologie, p. 591-634 and Antimykotika, p. 753–762].
10.1007/978-3-642-24167-3 Google Scholar
- 2 Kayser, F.H. et al. (eds.) (2010) Taschenlehrbuch Medizinische Mikrobiologie, 12 edn, Thieme, [ F.H. Kayser and E.C. Böttger, Mykologie, p. 360–387].
- 3 Lartey, P.A. and Moehle, Ch.M. (1997) Recent advances in antifungal agents. Annual Reports in Medicinal Chemistry, 32, 151–160.
- 4 Santo, R.Di. (2006) Recent developments in antifungal drug discovery. Annual Reports in Medicinal Chemistry, 41, 299–315.
- 5 Ostrosky-Zeichner, L. et al. (2010) An insight into the antifungal pipeline: selected new molecules and beyond. Nature Reviews/Drug Discovery, 9, 719–727.
- 6 Denning, D.W. and Bromley, M.J. (2015) How to bolster the antifungal pipeline. Science, 347, 1414–1416.
- 7 Monk, B.C. and Goffeau, A. (2008) Outwitting multidrug resistance to antifungals. Science, 321, 367–369.
- 8
Bell, A.S. (2007) Triazole Antifungals: Itraconazole, Fluconazole, Voriconazole, and Fosfluconazole in The Art of Drug Synthesis (ed. D.S. Johnson and J.J. Li), Wiley, p. 71–82.
10.1002/9780470134979.ch5 Google Scholar
- 9 Olin Mathieson (1958) US 2 908 611, USA-prior. 1954.
- 10 Godefroi, E.F. et al. (1969) J. Med. Chem., 12, 784.
- 11 Janssen (1973) US 3 717 655, USA-prior. 1968.
- 12 Janssen (1974) US 3 839 574, USA-prior. 1969.
- 13 Heeres, J. et al. (1979) J. Med. Chem., 22, 1003.
- 14 Janssen (1979) US 4 144 346, USA-prior. 1977.
- 15 Janssen (1980) US 4 223 036, USA-prior. 1977.
- 16 Janssen (1982) US 4 335 125, USA-prior. 1977.
- 17 Pfizer (1983) US 4 404 216, GB-prior. 1981.
- 18 Pfizer (1983) US 4 416 682, GB-prior. 1980.
- 19 Meeres, J. et al. (1984) J. Med. Chem., 27, 894.
- 20 Janssen (1981) US 4 267 179, USA-prior. 1978.
- 21 Dickinson, R.P. et al. (1996) Bioorg. Med. Chem. Lett., 6, 2031.
- 22 Pfizer (1994) US 5 278 175, GB-prior. 1990.
- 23 Pfizer (1998) US 5 773 443, GB-prior. 1990.
- 24 Saksena, A.K. et al. (1996) Tetrahedron Lett., 37, 5657.
- 25 Schering-Plough (1997) US 5 661 151, USA-prior. 1994.
- 26 Basilea (2001) US 6 300 353, EP-prior. 1998, 1999.
- 27 DPLA, inventor MSoukup (2012) US 8 207 352, USA-prior. 08.10.2009.
- 28 Basilea (2004) US 6 812 238, USA-prior. 2000.
- 29 Basilea (2006) US 7 151 182, EP-prior. 1999.
- 30 Basilea (2008) US 7 459 561, EP-prior. 1999.
- 31 Denning, D.W. (2003) Echinocandin antifungal drugs. The Lancet, 362, 1142–1151.
- 32 Duschinsky, R. et al. (1957) J. Am. Chem. Soc., 79, 4559.
- 33 Roche (1960) US 2 945 038, USA-prior. 1956.
- 34 Roche (1968) US 3 368 938, USA-prior. 1962, 1966.
- 35 Leonard, W.R. et al. (2007) J. Org. Chem., 72, 2335.
- 36 Merck & Co. (1995) US 5 378 804, USA-prior. 1993.
- 37 Merck & Co. (1999) US 5 936 062, USA-prior. 1997.
- 38 Merck & Co. (2007) US 9 214 768, USA-prior. 2002.
- 39 Tomishima, M. et al. (1999) J. Antibiot., 52, 674.
- 40 Fujisawa (2000) US 6 107 458, UK-prior. 1994, 1995.
- 41 Xellia Pharmaceut. (2011) US 9 132 163, USA-prior. 20.04.2011.
- 42 Debono, M. et al. (1995) J. Med. Chem., 38, 3271.
- 43 Eli Lilly (1999) US 5 932 543, USA-prior. 10.3.1992.
- 44 Eli Lilly (2005) US 6 916 784, L USA-prior. 19.03.1992.
- 45 Eli Lilly (2002) EP 561 639, USA-prior. 19.03.1992.
- 46 Vicuron (2007) US 7 198 796, USA-prior. 19.03.2002.
- 47 WHO “Global Tuberculosis Report 2015”, 20th Ed, WHO Library Cataloguing-in-Publication Data; ISBN 978 92 4 156505 9.
- 48 Gumbo, T. (2011) Chemotherapy of Tuberculosis, Mycobacterium Avium Complex Disease, and Leprosy , in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edn (eds L.L. Brunton, B.A. Chabner, and B.C. Knollmann), McGraw-Hill, p. 1549–1570.
- 49 Russell, D.G. et al. (2010) Tuberculosis: What we don't know, can, and does, hurt us. Science, 328, 852–856.
- 50 Dye, Chr. and Williams, B.G. (2010) The population dynamics and control of tuberculosis. Science, 328, 856–861.
- 51 Nature Outlook (2013) “Tuberculosis”, Nature 502 (7470) S1–S17.
- 52 Gutierrez-Lugo, M.-T. and Bewley, C. (2008) Natural products, small molecules, and genetics in tuberculosis drug development. J. Med. Chem., 51, 2606–2612.
- 53 Dover, L.G. and Coxon, G.D. (2011) Current status and research strategies in tuberculosis drug development. J. Med. Chem., 54, 6157–6165.
- 54 Jones, C.L. et al. (2015) Drug discovery for the developing world: progress at the Novartis Institute for Tropical Diseases. Nature Reviews/Drug Discovery, 14, 442–444.
- 55 Katsuno, K. et al. (2015) Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nature Reviews/Drug Discovery, 14, 751–758.
- 56 Arinaminpathy, N. and Dowdy, D. (2015) Understanding the incremental value of novel diagnostic tests for tuberculosis” in Nature Special (Modelling the impact of improved diagnostics), Supplement to Nature 528 (7580), S60–S67.
- 57 Zumla, A. et al. (2013) Advances in the development of new tuberculosis drugs and treatment regimens. Nature Reviews/Drug Discovery, 12, 388–404.
- 58 Lehmann, J. (1946) Lancet, 1, 6384.
- 59 Sheehan, J.C. (1948) J. Amer. Chem. Soc., 70, 1665.
- 60 v. Heyden Nachf. (1890) US 427 564, DE-prior. 1889.
- 61 Parke Davis (1951) US 2 540 104, USA-prior. 1949.
- 62 Parke Davis (1953) US 2 640 854, USA-prior. 1950.
- 63 American Cyanamid (1953) US 2 644 011, USA-prior. 1950.
- 64 Monsanto (1953) US 2 658 073, USA-prior. 1950.
- 65 Miles Labs. (1958) US 2 844 625, USA-prior. 1954.
- 66 Kuehl, F.A. et al. (1955) J. Am. Chem. Soc., 77, 2344; 2345; 2346.
- 67 Plattner, P.A. et al. (1957) Helv. Chim. Acta, 40, 1531.
- 68 Merck & Co. (1956) US 2 772 280, USA-prior. 1954.
- 69 Merck & Co. (1958) US 2 840 565, USA-prior. 1954.
- 70 Pfizer (1956) US 2 773 878, USA-prior. 1952.
- 71 Commercial Solvents (1957) US 2 789 983, USA-prior. 1954.
- 72 Merck & Co. (1958) US 2 845 433, USA-prior. 1955.
- 73 Sensi, P. et al. (1959) Ed. Sci., 14, 146.
- 74 Floss, H.G. and Yu, T.-W. (2005) Rifamycin – mode of action, resistance, and biosynthesis. Chem. Rev, 105, 621–632.
- 75 Lepetit (1964) US 3 150 046, GB-prior. 1958.
- 76 Lepetit (1975) US 3 871 965, IT-prior. 1973.
- 77 Lepetit (1981) US 4 267 274, IT-prior. 1973.
- 78 Maggi, N. and Sensi, P. (1966) Chemotherapia, 11, 285.
- 79 Lepetit (1967) US 3 342 810, GB-prior. 1964.
- 80 Holco Inv. (1979) US 4 174 320, GB-prior. 1977.
- 81 Archifar (1980) US 4 219 478, IT-prior. 1975.
- 82 Archifar (1977) US 4 017 481, IT-prior. 1975.
- 83 Archifar (1980) US 4 217 277, GB-prior. 1978.
- 84 Traxler, P. et al. (1990) J. Med. Chem., 33, 552.
- 85 Lepetit (1977) US 4 002 752, GB-prior. 1975.
- 86 Lepetit (1994) US 5 306 715, GB-prior. 1988.
- 87 Eli Lilly (1964) US 3 143 468, USA-prior. 1962.
- 88 Bristol-Myers (1977) US 4 026 766, USA-prior. 1976.
- 89 Roche (1952) US 2 596 069, USA-prior. 1952.
- 90 Distillers (1958) US 2 830 994, GB-prior. 1955.
- 91 Libermann, D. et al. (1956) Hebd. Séances Acad. Sci., 242, 2187, 2409.
- 92 Chimie et Atomistique Paris (1959) US 2 901 488, FR-prior. 1956.
- 93 Libermann, D. et al. (1958) Bull. Soc. Chim. France, 687, 694.
- 94 Libermann, D. et al. (1956) Hebd. Séances Acad. Sci., 242, 2187, 2409.
- 95 Chimie et Atomistique Paris (1959) US 2 901 488, FR-prior. 1956.
- 96 Libermann, D. et al. (1958) Bull. Soc. Chim. France, 687, 694.
- 97 Kushner, S. et al. (1949) J. Lab. Clin. Med, 33, 1249.
- 98 Muschenheim, C. et al. (1954) Amer. Rev. Tubercul., 70, 743. 72, 851 (1955).
- 99 American Cyanamid (1954) US 2 677 641, USA-prior 1952.
- 100 American Cyanamid (1957) US 2 780 624, USA-prior.1953.
- 101 Kushner, S. et al. (1952) J. Am. Chem. Soc., 74, 3617.
- 102 Hall, S.A. et al. (1940) J. Am. Chem. Soc., 62, 664.
- 103 Wilkinson, R.G. et al. (1961) J. Am. Chem. Soc., 83, 2212.
- 104 Wilkinson, R.G. et al. (1962) J. Med. Chem., 5, 835.
- 105 American Cyanamid (1965) US 3 176 040, USA-prior. 1960.
- 106 American Cyanamid (1971) US 3 553 257, USA-prior. 1966.
- 107 Bonati, F. et al. (1965) Farmaco (Pavia) Ediz. prat., 20, 381.
- 108 Andries, K. et al. (2005) Science, 307, 223.
- 109 Janssen (2009) US 7 498 343, USA-prior. 25.07.2002.
- 110 Janssen (2010) EP 1 527 050, USA-prior. 25.07.2002.
- 111 Janssen (2011) US 8 039 628, EP-prior. 25.05.2005.
- 112 Janssen (2013) US 8 546 428, EP-prior. 05.12.2006.
- 113 Sasaki, H. et al. (2006) J. Med. Chem., 49, 7854.
- 114 Otsuka Pharm. (2013) EP 1 555 267 B1, JP-prior. 05.12.2002.
- 115 Cler, M.T. et al. (2012) N. Engl. J. Med., 366, 2151.
- 116 Barry, V.C. et al. (1957) Nature, 179, 1013.
- 117 Geigy (1960) US 2 948 726, CH-prior. 1956.
- 118 Cholo, M.C. et al. (2011) J. Antimicrob. Chemother. doi: 10.1093/jac/dkr444.
- 119 I.G. Farben, (1939) GB 506 227, appln. 1938.
- 120 American Cyanamid (1940) US 2 227 400, USA-prior. 1939.
- 121 Lundbeck (2009) US 7 531 694, PCT-prior. 07.07.2004.
